Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Autor: Stewart J Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Hernan Picard, Sunfa Cheng, Denise E Chou, Feng Zhang, Jan Klatt, Daniel D Mikol

Publikováno v: The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-14 (2021)

Abstract Background In patients with migraine, overuse of acute medication, including migraine-specific medication (MSM) such as triptans and ergots, can lead to adverse health outcomes, including development of medication overuse headache. Here, we

Externí odkaz: https://doaj.org/article/f54ae6be4c9d4082adbb8b624f052db3

One-year sustained efficacy of erenumab in episodic migraine

Autor: Ian K. Wright, Gregor Broessner, Uwe Reuter, Robert A. Lenz, Daniel D. Mikol, Yngve Hallström, Feng Zhang, Jo H. Bonner, Hernan Picard, Jan Klatt, Peter J. Goadsby, Denise E. Chou

Publikováno v: Neurology
article-version (Version of Record) 3

ObjectiveTo assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine.MethodsPatients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or er

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::848d8fc94b80c248668e5065db0a6199
https://doi.org/10.1212/wnl.0000000000010019

Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies

Autor: Uwe Reuter, Nadia Tenenbaum, Daniel D. Mikol, Gabriel Paiva da Silva Lima, Feng Zhang, David Kudrow, Richard B. Lipton, David W. Dodick, Denise E. Chou

Publikováno v: Cephalalgia : an international journal of headache. 41(14)

Background Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine. Methods This post hoc analysis o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e71e2c5bf8e3cc0e8ea0605df7d053
https://pubmed.ncbi.nlm.nih.gov/34407654

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Autor: Daniel D. Mikol, Yngve Hallström, Hernan Picard, Feng Zhang, Denise E. Chou, Gregor Broessner, Messoud Ashina, Uwe Reuter, Sunfa Cheng, Jo H. Bonner, Jan Klatt, Stewart J. Tepper

Publikováno v: The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-14 (2021)
Tepper, S J, Ashina, M, Reuter, U, Hallström, Y, Broessner, G, Bonner, J H, Picard, H, Cheng, S, Chou, D E, Zhang, F, Klatt, J & Mikol, D D 2021, ' Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab : post-hoc analyses of episodic and chronic migraine clinical trials ', Journal of Headache and Pain, vol. 22, 81 . https://doi.org/10.1186/s10194-021-01292-w

Background In patients with migraine, overuse of acute medication, including migraine-specific medication (MSM) such as triptans and ergots, can lead to adverse health outcomes, including development of medication overuse headache. Here, we examined

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf29d95871686f7e265b3baed558f88
https://pubmed.ncbi.nlm.nih.gov/34301173

Timing and durability of response to erenumab in patients with chronic migraine

Autor: Denise E. Chou, Sylvia Lucas, Andrea Wang, James Scanlon, Jessica Ailani, Stewart J. Tepper, Todd J. Schwedt, Jan Klatt, Messoud Ashina, Gabriel Paiva da Silva Lima

Publikováno v: Tepper, S J, Lucas, S, Ashina, M, Schwedt, T J, Ailani, J, Scanlon, J, Klatt, J, Chou, D E, Wang, A & Paiva da Silva Lima, G 2021, ' Timing and durability of response to erenumab in patients with chronic migraine ', Headache, vol. 61, no. 8, pp. 1255-1263 . https://doi.org/10.1111/head.14193
Headache

Objective We sought to evaluate temporal response patterns to erenumab treatment in patients with episodic migraine. Background Although many patients treated with erenumab experience onset of efficacy as early as 1 week, clinical benefits of migrain

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88b6590704b5a1a3c4ddc39ec277ab55
https://curis.ku.dk/ws/files/302064329/Headache_2021_Tepper_Timing_and_durability_of_response_to_erenumab_in_patients_with_chronic_migraine.pdf